Currently, there are two types of hormonal treatments available for ER responsive breast cancer, which use either an anti-ER drug (e.g., tamoxifen) [9] or an aromatase inhibitor (e.g., letrozole) [10]. This evidence concerns the gene ESR1 and breast cancer.